中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

2024
  • 0
Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune response
. 2024 Oct 3;15:8569. doi: 10.1038/s41467-024-52902-5
Tan L, Yin T, Xiang H, Wang L, Mudgal P, Chen J, Ding Y, Wang G, Lim BJW, Huang Y, Huang D, Liang Y, Alexander PB, Xiang K, Wang E, Yan C, Ma Z, Tan M, Li QJ, Wang XF.

Breaking NGF-TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Nat Immunol. 2024 Jan 9;25(2):268–281. doi: 10.1038/s41590-023-01723-7
Yin T, Wang G, Wang L, Mudgal P, Wang E, Pan CC, Alexander PB, Wu H, Cao C, Liang Y, Tan L, Huang D, Chong M, Chen R, Lim BJW, Xiang K, Xue W, Wan L, Hu H, Loh YH, Wang XF, Li QJ.


EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion

. 2024 Jun 17;12(6):e008375. doi: 10.1136/jitc-2023-008375
Chen Y, Ouyang D, Wang Y, Pan Q, Zhao J, Chen H, Yang X, Tang Y, Wang Q, Li Y, He J, You JQ, Li Y, Xu C, Ren Y, Xie S, Li S, Lian J, Weng D, Xiang T, Xia JC.

The role of circadian clock in regulating cell functions: implications for diseases

. 2024 Mar 11;5(3):e504. doi: 10.1002/mco2.504
Lin Y, He L, Cai Y, Wang X, Wang S, Li F.


Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma


Wang P, Wang Z, Lin Y, Castellano L, Stebbing J, Zhu L, Peng L.
  • 上一篇:--
  • 下一篇:2021
04.18
2025
来源:
关键词:
相关阅读

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer